Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Conflict Of Interest Reform: With FDA Undecided, Consumer Groups Give Their Pitch

Executive Summary

FDA likes some rules in FDAAA and wants to continue discussion with Capitol Hill as changes are expected to be part of PDUFA legislation.

You may also be interested in...

CDER Advisory Panel Vacancies Remain High As Overall FDA Rates Improve

Empty slots on CDER advisory panels holding agency back from meeting goal vacancy rate as other centers fill more panel slots.

FDA Conflict Of Interest Screening Could Get Streamlined As Patient Involvement Increases

Agency is considering creating a pool of pre-screened patient representatives that would make it easier to place them in FDA-sponsored formal meetings and advisory committees.

Conflict of Interest Reform: Greatest Impact May Be Committee Vacancy Rate

FDA user fee reauthorization eliminates limits on waivers, which may ease the burden on FDA to fill open seats on its advisory committees. Vacancy rates have been as high as 24% in FY 2012.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts